

## Establishing Syva Methotrexate Assay on Siemens Dimension RxL Analyzer: Experience in a Tertiary Cancer Care Laboratory

Sir,

Methotrexate (MTX) is an antifolate drug, which is used in the treatment of neoplastic as well as some nonneoplastic diseases in varying doses. In high doses, it is used to treat malignant diseases such as systemic non-Hodgkin's lymphoma, osteosarcoma, central nervous system metastases, and acute lymphoblastic leukemia. While in low doses, it is used in the treatment of nonneoplastic diseases such as psoriasis and rheumatoid arthritis.<sup>[1]</sup> It acts by the mechanism of interfering with folate metabolism by inhibiting enzymes such as dihydrofolate reductase. Reduced folate is required for DNA synthesis by the cells. The multiplying malignant cells which require greater amount of this reduced folate are affected leading to cessation of DNA synthesis and eventual cell death. However, normal cell metabolism too gets affected due to the reduced folate levels. To counter this, supplementation of leucovorin which is a formulation of reduced folate is given to patients. This is also known as leucovorin rescue.<sup>[2]</sup> MTX toxicity is monitored using measurement of drug levels in the blood at timed intervals. The analytical range for the Syva EMIT MTX assay is 0.3–2  $\mu\text{Mol/L}$ ; however, in clinical practice, the levels of MTX are frequently maintained below this limit for leucovorin rescue and need to be measured. This study was undertaken to establish the Syva EMIT MTX assay on Siemens Dimension RxL analyzer and to evaluate its linearity below 0.3  $\mu\text{Mol/L}$ .

Syva EMIT MTX assay uses homogenous enzyme immunoassay technique. It is based on the principle of competitive binding between the drug in the assay and drug labeled with the enzyme glucose-6-phosphate dehydrogenase for the antibody binding site. Serum or plasma is used for testing. Samples collected in heparin, ethylenediaminetetraacetic acid, and oxalate anticoagulants are acceptable. Sample volume required is dependent on the instrument used. The kit includes reconstitution of antibody/substrate reagent A and enzyme reagent B. It also contains buffer concentrate and calibrators. Reconstituted reagents A and B are kept overnight at 2–8°C. Calibrator and buffer are reconstituted the next day. The working reagents A and B are prepared and filled in the cartridges. The reagents are now loaded on the analyzer and the

parameter is calibrated. The Syva EMIT MTX assay on Siemens Dimension RxL is a 5-point logit calibration assay. The calibrator values range from 0.2 to 2.0  $\mu\text{Mol/L}$ .

Following calibration, all the quality parameters such as precision, linearity, limit of detection, limit of blank, and EQAS-Trend analysis were assessed as per the standard laboratory protocol. For precision, five samples were processed five times and percentage of coefficient of variation (CV%) of the readings was determined. For linearity, calibrator of value 2.0  $\mu\text{Mol/L}$  was diluted serially with buffer and values of successive dilutions were measured. Values obtained were plotted against expected values and regression analysis was done. Samples known to not contain MTX drug were processed for limit of blank. Inter-instrument comparison analysis was carried out on 11 samples which were processed for MTX levels on Olympus AU 2700 fully automated biochemistry analyser (Beckman Coulter Inc, Brea, California, USA) with the Syva Emit Assay kit. Bio-Rad controls, level 1 with a mean value of 0.431  $\mu\text{Mol/L}$  and level 2 with a mean value of 1.185  $\mu\text{Mol/L}$ , were used for internal quality controls (IQCs). Mean, standard deviation, and CV% were calculated. The linearity was 0.17–1.98  $\mu\text{Mol/L}$ , the  $R^2 = 0.987$ , and y-intercept of 1.03 was observed. The limit of detection was 0.17  $\mu\text{Mol/L}$  and limit of blank was 0  $\mu\text{Mol/L}$ . The inter-instrument comparison analysis by linear regression showed  $R^2 = 0.991$  and y-intercept of 0.871. The IQC showed CV% of 0.6% for level 1 and 2.8% for level 2 [Table 1].

The linearity obtained in our study was higher compared to that obtained by Borgman *et al.*<sup>[3]</sup> on Siemens Viva-E instrument. However, it was much lower compared to the lower limit of 0.3  $\mu\text{Mol/L}$  claimed by the kit manufacturer. This corroborates with findings by Wilson *et al.*,<sup>[4]</sup> who reported lower sensitivity for MTX levels below 0.2  $\mu\text{Mol/L}$  with this assay. The CV% for both levels of controls was comparable in our study to that claimed on Siemens Viva-E instrument at <4%. The imprecision range in our study was much lower at 0.6–2.8% compared to another study by Suh-Lailam *et al.*,<sup>[5]</sup> which showed an imprecision range of 5.31–8.43%. In conclusion, although the Siemens Syva EMIT MTX assay claims an analytical range of 0.3–2.0  $\mu\text{Mol/L}$ , values up to 0.17  $\mu\text{Mol/L}$  can be reported on Siemens Dimension RxL analyzer.

### Financial support and sponsorship

Nil.

**Table 1: Statistical results for evaluation of the methotrexate assay on Siemens Dimension RxL analyzer**

Parameter	Value
Linearity ( $\mu\text{Mol/L}$ )	0.17-1.98
R	0.987
y-intercept	1.03
Limit of detection ( $\mu\text{Mol/L}$ )	0.17
Limit of blank ( $\mu\text{Mol/L}$ )	0
Percentage of coefficient of variation	
Level 1 (mean=0.143 $\mu\text{Mol/L}$ )	0.6
Level 2 (mean=1.185 $\mu\text{Mol/L}$ )	2.8
Inter-instrument comparison with AU2700 (Beckman Coulter Inc.)	
R	0.991
y-intercept	0.871

**Conflicts of interest**

There are no conflicts of interest.

**Preeti Chavan, Vivek Bhat,  
Ashwadeep Karmore, Rajani Mohite,  
Swati Waykar, Hemali Kadu**

Composite Laboratory, Advanced Centre for Treatment,  
Research and Education in Cancer-Tata Memorial Centre,  
Mumbai, Maharashtra, India

**Address for correspondence:**  
Dr. Preeti Chavan,  
E-mail: pchavan@actrec.gov.in

**REFERENCES**

- Oellerich M, Engelhardt P, Schaadt M, Diehl V. Determination of methotrexate in serum by a rapid, fully mechanized enzyme immunoassay (EMIT). *J Clin Chem Clin Biochem* 1980;18:169-74.
- Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, *et al.* Harrison's Principles of Internal Medicine. 17<sup>th</sup> ed., Ch. 81. USA: The McGraw-Hill Companies, Inc.; 2008.
- Borgman MP, Hiemer MF, Molinelli AR, Ritchie JC, Jortani SA. Improved sensitivity for methotrexate analysis using enzyme multiplied immunoassay technique on the Siemens Viva-E instrument. *Ther Drug Monit* 2012;34:193-7.
- Wilson JF, Tsanaclis LM, Barnett K. External quality assessment of Syva Emit and Abbott TDx II assays for methotrexate in serum. *Ther Drug Monit* 1996;18:721-3.
- Suh-Lailam BB, Juenke JM, Thompson CD, Johnson-Davis KL. Performance Characteristics of Three Assays for the Therapeutic Drug Monitoring of Methotrexate. Abstract Presentation, Thirteenth International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, USA; September, 2013.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

**Access this article online****Quick Response Code:**

**Website:**  
[www.jlponline.org](http://www.jlponline.org)

**DOI:**  
10.4103/0974-2727.187923

**How to cite this article:** Chavan P, Bhat V, Karmore A, Mohite R, Waykar S, Kadu H. Establishing syva methotrexate assay on siemens dimension RxL analyzer: Experience in a tertiary cancer care laboratory. *J Lab Physicians* 2017;9:67-8.